In this issue:
Spartalizumab + dabrafenib + trametinib for BRAF V600-mutant unresectable or metastatic melanoma
Biomarkers of treatment benefit with atezolizumab + vemurafenib + cobimetinib in BRAF V600 mutation-positive melanoma
MAPKinase inhibition after failure of ICI in advanced melanoma
Pembrolizumab vs placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma
Global burden of cutaneous melanoma in 2020 and projections to 2040
Five-year outcomes of a melanoma screening initiative
Polygenic risk scores for melanoma risk prediction
Long-term control of melanoma adrenal metastasis treated with radiotherapy
Time interval between diagnostic excision of a primary melanoma and SNB and influence on SN-positivity rate or survival outcomes
Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy
Please login below to download this issue (PDF)